The global AI in Bioinformatics Market in 2026  is witnessing remarkable growth driven by the increasing adoption of artificial intelligence technologies in genomics, drug discovery, and personalized medicine. According to Fortune Business Insights, the market size was valued at USD 1.06 billion in 2025 and is projected to grow from USD 1.22 billion in 2026 to USD 4.80 billion by 2034, exhibiting a strong CAGR of 18.63% during the forecast period. The rapid evolution of machine learning algorithms and big data analytics is significantly enhancing bioinformatics workflows, enabling faster and more accurate biological data interpretation.

AI integration in bioinformatics is revolutionizing healthcare and life sciences by improving genomic sequencing, disease prediction, and biomarker discovery. The growing demand for precision medicine and advancements in next-generation sequencing (NGS) technologies are further accelerating market expansion. In 2025, North America dominated the market with a share of 41.51%, owing to the strong presence of biotechnology companies, advanced research infrastructure, and increased funding in AI-driven healthcare solutions.

Market Drivers & Restraints:

Drivers:

• Increasing demand for personalized medicine and precision therapeutics.
• Rising adoption of AI-based tools in genomic sequencing and drug discovery.
• Growth in healthcare data generation requiring advanced analytical solutions.
• Advancements in machine learning, deep learning, and cloud computing technologies.
• Increased investment by public and private organizations in bioinformatics research.

Restraints:

• High implementation costs associated with AI technologies.
• Data privacy and security concerns in handling genomic data.
• Lack of skilled professionals in AI and bioinformatics integration.
• Regulatory challenges and ethical concerns related to AI usage in healthcare.

Market Report Coverage:

The AI in bioinformatics market report provides a comprehensive analysis of key aspects such as market size, share, growth rate, and future outlook. It includes detailed insights into emerging trends, technological advancements, and competitive developments. The report also covers market segmentation, regional analysis, and strategic initiatives undertaken by key industry players. Additionally, it evaluates market dynamics including drivers, restraints, opportunities, and challenges influencing growth.

Market Competitive Landscape:

The market is highly competitive with the presence of several global and regional players focusing on innovation and strategic collaborations. Companies are investing heavily in AI-based platforms to enhance their bioinformatics capabilities. Partnerships, mergers, and acquisitions are common strategies adopted to strengthen market position and expand product portfolios.

Top Companies in the Market:

• TEMPUS (U.S.)
• SOPHiA GENETICS (Switzerland)
• DNAnexus, Inc. (U.S.)
• Fabric Genomics, Inc. (U.S.)
• Recursion (U.S.)
• BioSymetrics, Inc. (U.S.)
• Owkin, Inc. (France)
• BenevolentAI (U.K.)
• Illumina Inc. (U.S.)
• DEEP GENOMICS (Canada)

Market Segments:

The AI in bioinformatics market is segmented based on component, application, and end-user.

By Component (Software & Services)

By Deployment (Cloud-based, On-Premise, & Hybrid)

By Technology (Machine Learning & Deep Learning, Natural Language Processing, & Others)

By Application (Genomics & Sequence Analysis, Multi-omics Analysis, Protein Structure & Functional Analysis, Drug Discovery & Molecular Design, Clinical Genomics / Precision Medicine, & Others)

By End User (Pharmaceutical & Biotechnology Companies, CROs/CDMOs, Academic & Research Institutes, & Others)

Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/ai-in-bioinformatics-market-115851 

Market Regional Insights:

North America holds the largest share in the AI in bioinformatics market, supported by strong technological advancements and high adoption of AI in healthcare. The presence of leading biotechnology companies and research institutions further boosts regional growth.

Europe is also experiencing significant growth due to increased government initiatives and funding for AI research in life sciences. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by expanding healthcare infrastructure, rising investments in biotechnology, and growing awareness of precision medicine.

Future Market Scope:

The future of the AI in bioinformatics market looks promising, with continuous advancements in artificial intelligence and data analytics technologies. The increasing integration of AI with cloud computing and big data platforms is expected to enhance scalability and efficiency in bioinformatics processes.

Emerging trends such as AI-driven clinical decision support systems, real-time genomic analysis, and predictive healthcare models are anticipated to create new growth opportunities. Additionally, the rising focus on personalized healthcare and precision medicine will further accelerate market expansion in the coming years.

As research activities continue to grow and data generation increases, AI will play a critical role in transforming bioinformatics by enabling faster insights and improved accuracy in biological data interpretation.

Recent Industry Developments:

• March 2026: Tempus announced a strategic collaboration with Merck to accelerate AI-driven precision medicine and biomarker discovery in oncology using Tempus’ data and analytics capabilities.
• February 2026: Tempus announced HRD-RNA, a new AI-driven pan-cancer algorithm built on a 1,660-gene logistic regression model to improve identification of homologous recombination deficiency and support treatment selection.

Conclusion:

The AI in bioinformatics market is poised for substantial growth, driven by technological advancements and increasing demand for data-driven healthcare solutions. With a strong CAGR of 18.63%, the market is expected to transform the life sciences industry by enabling innovative approaches to disease diagnosis, treatment, and drug discovery. As key players continue to invest in AI technologies and strategic collaborations, the market will witness significant expansion and innovation through 2034.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: [email protected]